-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3740 Immune Checkpoint Inhibitors in Primary Mediastinal B-Cell Lymphoma: A Monocentric Real-Life Experience and Future Potential

Program: Oral and Poster Abstracts
Session: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II
Hematology Disease Topics & Pathways:
Research, Clinical Research, Real-world evidence
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Pier Luigi Zinzani, MD1, Lisa Argnani, PhD2*, Martina Cantelli3*, Gabriele Gugliotta, MD4*, Beatrice Casadei, MD5*, Marianna Gentilini, MD3*, Vittorio Stefoni3*, Cinzia Pellegrini6*, Alice Morigi3*, Nicole Fabbri3*, Giulia Gabrielli, MD2*, Camilla Mazzoni, MD7*, Pierluca Maglio3*, Gianmarco Bagnato7* and Alessandro Broccoli, MD, PhD2*

1Department of Medical and Surgical Sciences, Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Bologna, Italy
2Institute of Hematology “L. e A. Seràgnoli”, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
3Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
4IRCCS Azienda Ospedaliero–Universitaria di Bologna, Istituto di Ematologia "Sèragnoli", Italy, Bologna, Italy, Bologna, Italy
5IRCCS Azienda Ospedaliero-Universitaria di Bologna  Istituto di Ematologia “Seràgnoli”, Bologna, Italy
6IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, ITA
7Department of Medical and Surgical Sciences, University of Bologna, Bologna, ITA

Patients with relapsed or refractory primary mediastinal B cell lymphoma (R/R PMBCL) have a poor prognosis, with an overall response rate (ORR) to salvage chemotherapy of 25% and a 2-year overall survival (OS) rate after diagnosis of R/R PMBCL of 15%. PMBCL cells overexpress programmed cell death 1 ligand (PDL1), enabling evasion of immune surveillance. Immune checkpoint inhibitors (ICIs) restore the T-lymphocyte mediated anti-tumor effect and have received FDA approval for the therapy of classical Hodgkin lymphoma and PMBCL. Here we presented our monocentric experience with ICIs in the context of R/R PMBCL.

Forty-six patients were treated with pembrolizumab (n=31) or with the combination of nivolumab and brentuximab vedotin (nivoBV, n=15) after a median number of previous therapies of 2 (range 1-6), 72% were female. No statistical significant difference occurred in the main characteristics in the two cohorts.

After a median number of 3 cycles (range 1-20) for pembrolizumab and 2 for nivoBV (range 1-52), best ORR was for pembrolizumab 54.1% (with 16 complete response [CR]) and 72.7% for nivoBV (with 6 CR). Best response was reached at a median of 3 (range 1-7) cycles for pembrolizumab and of 2 (range 1-4) for nivoBV. Final global ORR was 48.6% with 40.5% of CR rate. Nine patients underwent ICI as bridging therapy (BT) for CAR T-cell obtaining 6 CR, while other 3 patients initially candidates to use ICI as BT to CAR T were re-scheduled to continue ICI that became to all effects a further line of therapy (all obtained a CR after 35-36 cycles and are still in continuous CR).

Seventy-two adverse events (AE) occurred in 34 patients, 17 ones were of grade ≥3 and 10 were classified as immune-related AE. In the nivoBV cohort more extra-hematological AEs occurred, both overall (p = 0.006) and considering only those of grade 3-4 (p = 0.0301). Three patients in the nivoBV cohort had an early ICI discontinuation due to an extra-hematological AE. Hematological toxicity was represented only by 9 neutropenia in 9 patients all of grade ≥3 and judged related to therapy.

Nineteen patients underwent further therapy after ICI. At a median follow up for the whole study population of five years, median OS was not reached, progression-free survival (PFS) was 47.1% at 8 years with a plateau reached after ten months, disease free survival (DFS) was 100%, and no statistical difference occurred between the two subgroups. At the latest follow up, 28 patients were still alive, 25 in CR and 3 in PR on initial treatment. Among patients in CR, 16 are maintaining continuous CR without any kind of consolidation, 8 achieved CR after CAR T-cell and 1 patient in CR received consolidation therapy with autologous stem cell transplantation.

In conclusion our results demonstrate that ICI therapy for R/R PMBCL is associated with high response rate and durable outcomes. The study is still ongoing to expand the sample size due to the rarity of the disease to further investigate the potential of ICIs as BT to CAR T-cell or transplantation and to identify the specific subset of patients who can be cured only with ICIs.

Disclosures: Zinzani: CELLTRION, GILEAD, JANSSEN-CILAG, BMS, SERVIER, ASTRAZENECA, TAKEDA, ROCHE, KYOWA KIRIN, Incyte, Beigene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD, EUSAPHARMA, NOVARTIS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; SECURA BIO, ADC Therap, Sandoz: Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH